On May, 10 IntelGenx Technologies Corp. (IGX) Analysts See $-0.02 EPS

May 3, 2018 - By Charla Downs

IntelGenx Technologies Corp. (CVE:IGX) Corporate Logo

IntelGenx Technologies Corp. (CVE:IGX)’s earnings report is expected by WallStreet on May, 10, Zacks reports. EPS of $-0.02 is 100.00 % down from 2017’s $-0.01 EPS. Last quarter $-0.03 EPS was reported. Analysts predicts -33.33 % EPS growth this quarter. Ticker’s shares touched $0.87 during the last trading session after 5.43% change.Currently IntelGenx Technologies Corp. is after 0.00% change in last May 3, 2017. IGX has also 3,325 shares volume. The stock underperformed the S&P500 by 11.55%.

IntelGenx Technologies Corp., a drug delivery company, develops novel oral immediate-release and controlled-release products for the pharmaceutical market.The company has $62.96 million market cap. It offers RIZAPORT, an oral thin film formulation of rizatriptan benzoate for the treatment of acute migraines.Currently it has negative earnings. The company's products under development comprise INT0001/2004, an anti-hypertension drug; INT0004/2006, an antidepressant; INT0007/2006 for the treatment of erectile dysfunction; INT0010/2006 for the treatment of neuropathic pain and nausea in cancer patients; INT0027/2011 to treat opioid dependence; INT0036/2012 for schizophrenia; and INT0043/2015 to treat mild cognitive impairment and Alzheimer's disease.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: